2015年7月16日木曜日

ATS/ERS/JRS/ALAT合同臨床実践ガイドライン:特発性肺線維症 2011年分のアップデートという形で発表





An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu, et. al.; on behalf of the ATS, ERS, JRS, and ALAT
Read More: http://www.atsjournals.org/doi/abs/10.1164/rccm.201506-1063ST#.VadLZpe2q3M



http://www.thoracic.org/statements/resources/interstitial-lung-disease/IPF-Exec-Sum.pdf
http://www.thoracic.org/statements/resources/interstitial-lung-disease/IPF-Full-length.pdf



Question 1: Should Patients with IPF Be Treated with Anticoagulation?

Question 2: Should Patients with IPF Be Treated with Imatinib, a Tyrosine Kinase Inhibitor?

Question 3: Should Patients with IPF Be Treated with Combination Prednisone, Azathioprine, andN-Acetylcysteine?

Question 4: Should Patients with IPF Be Treated with Ambrisentan, a Selective ER-A Endothelin Receptor Antagonist?

Question 5: Should Patients with IPF Be Treated with Nintedanib, a Tyrosine Kinase Inhibitor?
Question 6: Should Patients with IPF Be Treated with Pirfenidone?

Question 7: Should Patients with IPF Be Treated with Sildenafil,a Phosphodiesterase-5 Inhibitor?

Question #8: Should Patients with IPF Be Treated with Bosentan or Macitentan, Dual Endothelin Receptor Antagonists (ER-A and ER-B)?








Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)
15 July 2015
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/15_july_2015_ipf.html

0 件のコメント:

コメントを投稿

noteへ実験的移行

禁煙はお早めに! 米国における人種・民族・性別による喫煙・禁煙での死亡率相違|Makisey|note 日常生活内の小さな身体活動の積み重ねが健康ベネフィットをもたらす:VILPA|Makisey|note